Abstract Details

Read the abstract and find the presentation below

Full text and presentation details

I – Gene & Cell Therapy Trials in Progress -> Gene & Cell Therapy Trials in Progress

1550: A Phase 1, First in Human (FIH) Study of Autologous Anti-HER2 Chimeric Antigen Receptor Macrophage (CAR-M) in Participants (pt) with HER2 Overexpressing Solid Tumors

Type: Poster Session

Poster Board Number: 1550
Presentation Details
Session Title: Friday Poster Session
Start Time: 5/19/2023 12:00
End Time: 5/19/2023 14:00

Background: Macrophages are abundant in the solid tumor microenvironment (sTME) and can exhibit both pro- and anti-tumor functions. Macrophages can be redirected by CAR expression to phagocytose cancer cells in an antigen-specific manner. CAR-M can reprogram the sTME and present neoantigens to T cells, leading to epitope spreading and anti-tumor immunity. CT-0508 is comprised of autologous monocyte-derived proinflammatory macrophages expressing an anti-HER2 CAR. Pre-clinical studies showed that CT-0508 induced targeted cancer cell phagocytosis while sparing normal cells, decreased tumor burden, prolonged survival, and was safe and effective. Notably, anti-HER2 CAR-M treatment led to activation of the sTME, with infiltration of CD8+ and CD4+ T cells, NK cells, dendritic cells, and increased activated CD8+ tumor infiltrating lymphocytes. In a pre-clinical model of advanced solid tumor resistant to PD1 blockade, mice treated with anti-HER2 CAR-M combined with a PD1 blocking antibody demonstrated improved tumor control, overall survival, and TME activation compared to either treatment alone, indicating synergy and capacity for CAR-M to sensitize solid tumors to checkpoint blockade. Methods: This Phase 1, FIH study is evaluating safety, tolerability, cell manufacturing feasibility, trafficking, TME activation, and preliminary evidence of efficacy of investigational product CT-0508 in 18 pt with locally advanced (unresectable) /metastatic solid tumors overexpressing HER2. Pt previously treated with anti-HER2 therapies are eligible. Filgrastim mobilized autologous CD14+ monocytes are collected by apheresis, followed by manufacturing and cryopreservation. Group 1 pt (n = 9; enrollment complete) received fractionated doses over Days 1, 3, and 5. Group 2 pt (n = 9) receive CT-0508 as a single infusion on D1. Additional cohorts include: CT-0508 co-administered with pembrolizumab and CT-0508 monotherapy administered intraperitoneally in pt with peritoneal predominant disease. Correlative assessments include pre- and post-treatment biopsies and blood samples for safety (immunogenicity), trafficking (qPCR, RNA in situ hybridization), CT-0508 persistence in blood and tumor, target antigen engagement, TME modulation (single cell RNA sequencing), immune response (TCR sequencing) and others.

Joanne Mortimer1, Yara Abdou2, E. Claire Dees2, Naoto Ueno3, Melissa Johnson4, Richard T. Maziarz5, Jennifer Specht6, Yuan Yuan7, Paula Pohlmann8, Mathew Angelos9, Saar Gill10, Amy Ronczka11, Thomas Condamine11, Dan Cushing11, Michael Klichinsky11, Debora Barton11, Ramona Swaby11, Kim ReissBinder9

1City of Hope, Duarte, CA,2University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC,3University of Hawaii, Honolulu, HI,4Sarah Cannon Research Institute, Nashville, TN,5Oregon Health & Science University, Portland, OR,6Fred Hutchinson Cancer Center, Seattle, WA,7Cedars Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA,8The University of Texas M.D. Anderson Cancer Center, Houston, TX,9University of Pennsylvania Abramson Cancer Center, Philadelphia, PA,10University of Pennsylvania Abramson Cancer Center,, Philadelphia, PA,11Carisma Therapeutics, Philadelphia, PA
 J. Mortimer: None.

Find This Presentation

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.